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Abstract
Background: Although the PBS-IIc SELDI-TOF MS apparatus has been extensively used in the
search for better biomarkers, issues have been raised concerning the semi-quantitative nature of
the technique and its reproducibility. To overcome these limitations, a new SELDI-TOF MS
instrument has been introduced: the PCS 4000 series. Changes in this apparatus compared to the
older one are a.o. an increased dynamic range of the detector, an adjusted configuration of the
detector sensitivity, a raster scan that ensures more complete desorption coverage and an
improved detector attenuation mechanism. In the current study, we evaluated the performance of
the old PBS-IIc and new PCS 4000 series generation SELDI-TOF MS apparatus.
Methods: To this end, two different sample sets were profiled after which the same ProteinChip
arrays were analysed successively by both instruments. Generated spectra were analysed by the
associated software packages. The performance of both instruments was evaluated by assessment
of the number of peaks detected in the two sample sets, the biomarker potential and
reproducibility of generated peak clusters, and the number of peaks detected following serum
fractionation.
Results:  We could not confirm the claimed improved performance of the new PCS 4000
instrument, as assessed by the number of peaks detected, the biomarker potential and the
reproducibility. However, the PCS 4000 instrument did prove to be of superior performance in
peak detection following profiling of serum fractions.
Conclusion:  As serum fractionation facilitates detection of low abundant proteins through
reduction of the dynamic range of serum proteins, it is now increasingly applied in the search for
new potential biomarkers. Hence, although the new PCS 4000 instrument did not differ from the
old PBS-IIc apparatus in the analysis of crude serum, its superior performance after serum
fractionation does hold promise for improved biomarker detection and identification.
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Background
The development of mass spectrometry (MS) for the anal-
ysis of complex protein mixtures has greatly enhanced the
possibility of large-scale protein profiling studies. Protein
profiling studies are generally performed using a top-
down approach starting with a mixture of intact proteins
and peptides. After sample pre-fractionation, e.g. by two-
dimensional polyacrylamide gel electrophoresis (2D-
PAGE), proteins are identified either by peptide mass fin-
gerprinting using tryptic digestion and/or tandem MS.
Mass spectrometry for protein profiling is particularly
important for the low-molecular-weight fraction of the
proteome, since the use of immunological assays is lim-
ited due to a lack of antibodies for these peptides. Up until
recently, real high-throughput technologies for mass spec-
trometric protein profiling have been lacking. Two recent
applications of matrix-assisted laser desorption ionisation
– time of flight mass spectrometry (MALDI-TOF MS) com-
bine sample pre-fractionation with MS, facilitating the
analysis of many samples at the time. A magnetic beads-
based assay using beads with different chromatographic
affinities is available from Bruker Daltonics [1]. Alterna-
tively, surface-enhanced laser desorption ionisation –
time of flight mass spectrometry (SELDI-TOF MS; Bio-Rad
Laboratories, Hercules, CA) can be used to profile biolog-
ical matrices on arrays with different surface chemistries.
A ProteinChip Interface is available for hybrid quadrupole
– time of flight mass spectrometers (PCI-QqTOF; e.g.
QSTAR, Applied Biosystems/MDS SCIEX, Foster City, CA,
USA), permitting QqTOF analysis of ProteinChip arrays.
Although QqTOF platforms have both tandem MS capa-
bility and superior mass accuracy, it suffers from
decreased sensitivity and a limited data acquisition range
(up to 4 kDa), compared to the SELDI-TOF MS platform
(up to 200 kDa).
The SELDI-TOF MS technology has been extensively used
for the assessment of tissue, serum and plasma to find
diagnostic, prognostic or therapy-predictive biomarkers
for diseases, especially cancer [2-8]. However, issues have
been raised concerning the semi-quantitative nature of the
technique and its reproducibility [9-11]. The first genera-
tion SELDI-TOF MS instruments (PBS-II and PBS-IIc) gen-
erate spectra with a fixed maximum signal, which is set to
100. Protein abundances exceeding this maximum satu-
rate the detector and are cut off to 100, neglecting the
excess abundance and leading to underestimated peak
intensities from both the saturated peak and its following
peak, as the detector remains saturated for some time
[12]. Furthermore, settings for laser intensity and detector
sensitivity are not easily optimised to generate unsatu-
rated spectra for all the samples to be measured. To over-
come these limitations a new SELDI-TOF MS instrument
has been introduced: the PCS 4000 series. Changes in this
apparatus compared to the older ones are: 1) the
increased dynamic range of the detector, so that saturation
is less likely to occur, 2) the special configuration for sen-
sitivity in the high mass range for better detection of pro-
teins > 100 kDa, 3) a so-called Synchronised Optical Laser
Extraction, which scans each spot in a raster to ensure
complete desorption coverage, 4) a detector attenuation
mechanism, enabling signal reduction up to a specified
mass and preventing saturation by matrix molecules. Fur-
thermore, instead of using arbitrary units, peak intensities
are scaled in µA, corresponding to the real electric current
generated by the impact of ions onto the detector. Laser
intensity settings are in nJ [13].
These improvements should lead to better reproducibility
of peak intensities and detection of more peaks. Yet, the
ultimate gain would be that this leads to more and better
biomarker candidates. We chose to assess these claims by
serum protein profiling of two different cohorts of cancer
patients and matched controls on both the PBS-IIc and
the PCS 4000 SELDI-TOF MS. The data generated on each
platform were analysed by the associated software pack-
ages. Furthermore, the PBS-IIc generated data were ana-
lysed by the software package associated with the PCS
4000 apparatus, to assess the influence of the different
software packages. The numbers of detected and signifi-
cantly different peaks on both instruments were com-
pared, as was the potential of each data set to yield a
reliable classification of patients and controls. Further-
more, the reproducibilities of the instruments were com-
pared. Lastly, we also profiled serum fractions and
assessed the difference in number of peaks detected
between the PBS-IIc and PCS 4000 instruments.
Methods
Chemicals
All used chemicals were obtained from Sigma, St. Louis,
MO, USA, unless stated otherwise.
Patient samples
The performances of both apparatus were assessed with
two distinct sample sets. A first set of 45 sera from color-
ectal cancer (CRC) patients and 43 matched controls
(CON) was prospectively collected between July 2003 and
October 2005 (referred to as the CRC set). The second set
consisted of 45 sera from breast cancer (BC) patients and
46 matched normal women (CON), collected between
January 2003 and July 2005 (referred to as the BC set).
Both sets were obtained at the Netherlands Cancer Insti-
tute, in Amsterdam, The Netherlands. Sample collection
was performed with individuals' informed consent after
approval by the institutional review boards.
Serum fractionation
Serum samples from three normal women were fraction-
ated in duplicate on QhyperD beads with a strong anionBMC Medical Genomics 2008, 1:4 http://www.biomedcentral.com/1755-8794/1/4
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exchange moiety (Bio-Rad Labs), according to manufac-
turer's protocol. Sample fractionation was performed with
a Biomek 3000 Laboratory Automation Workstation
(Beckman Coulter Inc.). First, sera were denatured with 9
M urea/2% 3 [(3-cholamidepropyl)-dimethylammonio]-
propane sulfonate (CHAPS). After binding of denatured
serum to the beads, the flow-through was collected and
bound proteins were subsequently eluted with buffers
with pH from 9 to 3. Remaining proteins were finally
eluted with an organic buffer.
Protein profiling
For profiling of whole serum each sample was analysed
according to previously developed protocols [4]. CRC
samples and their matched controls were first denatured
with 9 M urea/2% CHAPS/1% dithiotreitol. Then, each
sample was applied in triplicate on CM10 arrays (weak
cation exchange chromatography) with 20 mM sodium
phosphate pH 5/0.1% TritonX-100 as a binding buffer
and 20 mM sodium phosphate pH 5 as a wash buffer. BC
samples and their matched controls were denatured in 9
M urea/2% CHAPS, after which each sample was applied
in duplicate on IMAC30 arrays (immobilised metal affin-
ity capture chromatography). Prior to sample application,
IMAC30 arrays were charged twice with 50 µL 100 mM
nickel sulphate (Braun, Emmenbrücke, Germany), fol-
lowed by three rinses with deionised water. Phosphate
Buffered Saline (PBS; 0.01 M) pH 7.4/0.5 M sodium chlo-
ride/0.1% TritonX-100 was applied as a binding buffer
and PBS pH 7.4/0.5 M sodium chloride as a wash buffer.
For both sample sets, a 50% sinapinic acid (SPA; Bio-Rad
Labs) solution in 50% acetonitrile (ACN)/0.5% trifluoro-
acetic acid (TFA) was used as energy absorbing matrix.
Profiling of fractionated serum was performed on both
CM10 chips and IMAC30 arrays. Binding and wash buff-
ers were 100 mM sodium acetate pH 4 and 50 mM HEPES
buffer for CM10. For IMAC30, 100 mM copper sulphate
was used as charging solution, 100 mM sodium acetate as
neutralizing buffer and 100 mM sodium phosphate pH 7/
0.5 M sodium chloride as binding and wash buffer (all:
Bio-Rad Labs). A solution of 50% SPA in 50% ACN/0.5%
TFA was used as matrix.
During all profiling experiments arrays were assembled in
96-well format bioprocessors (Bio-Rad Labs), which were
placed on a platform shaker at 350 rpm. Arrays were
equilibrated twice with 200 µL of binding buffer, incu-
bated with denatured sample or QHyperD serum fraction
for 30 min and, after binding, washed twice with binding
buffer, followed by two washes with wash buffer. Lastly,
arrays were rinsed with deionised water. After air-drying,
two times 1 µL of matrix was applied to the array spots.
SELDI-TOF MS analysis of all datasets was performed with
both the PBS-IIc and the PCS 4000 ProteinChip Reader
(Bio-Rad Labs). Data acquisition and processing were
optimised for each sample set separately. Each spot was
read twice, once with the PCS 4000 and once with the
PBS-IIc instrument. Measurement settings for each appa-
ratus and sample set are summarised in Table 1. M/z val-
ues were calibrated externally with All-in-One peptide
standard (Bio-Rad Labs).
Statistics and bioinformatics
To account for possible differences in data processing by
the different software packages, data from the PBS-IIc
were analysed with the ProteinChip Software, version 3.1
(Bio-Rad Labs) as well as with Ciphergen Express™ version
3.0.6. (Bio-Rad Labs). PCS 4000 data were only processed
with the latter package. The PBS-IIc-generated spectra ana-
lysed by the ProteinChip Software and Ciphergen
Express™ respectively will further be referred to as "data set
1a" and "data set 1b". The PCS 4000-generated spectra,
analysed by Ciphergen Express™ will be referred to as
"data set 2".
Spectra from the CRC and BC sets were analysed sepa-
rately. Acquired spectra from each set were compiled and
analysed as a whole. Both the ProteinChip and Ciphergen
Express™ software spectra were baseline subtracted with
the following settings: smooth before fitting baseline: 25
points, fitting width: 10 times expected peak width. Filter-
ing was "on" using an average width of 0.2 times the
expected peak width. The noise was calculated from 2000
or 1000 to 200,000 Da for the CRC and BC set respec-
tively. Spectra were normalised to the total ion current in
the same m/z range. For peak clustering with the Protein-
Chip Software, the Biomarker Wizard (BMW; Bio-Rad
Labs) application was used. For clustering with the
Ciphergen Express™ software (Bio-Rad Labs), identical
clustering conditions were defined (see Table 1). In each
set, peaks were auto-detected starting from 2000 Da.
For the CRC and BC set, peak intensities from the tripli-
cate (CRC) and duplicate (BC) analyses were averaged
and mean peak intensities between groups compared by
the non-parametric Mann-Whitney U (MWU) test (p <
0.01 considered statistically significant). For the CRC set,
the median CV in each sample set was calculated from the
CV's of the triplicate analyses for all clustered peaks in
each data set as well as for all common peaks present in
each of the three data sets.
For the BC set, Spearman's rank correlation coefficient
was calculated on peak intensities in each duplicate anal-
ysis for all three data sets. The majority of peaks (> 50%)
detected spectrum wide in the three data sets are of rela-
tively low average intensity (< 5), increasing the chance ofBMC Medical Genomics 2008, 1:4 http://www.biomedcentral.com/1755-8794/1/4
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finding potential biomarkers in the low intensity range.
Hence, the reproducibility of peaks in the low intensity
range is of special interest. However, correlation analyses
are influenced by outliers (e.g. the few high intensity
peaks detected), even when using non-parametric statis-
tics. We therefore chose to assess the reproducibility in
subsets of peaks, starting with inclusion of the 10%, 20%,
30%, etc. of peaks with lowest intensity, and ending with
inclusion of all peaks detected. Spearman's rank correla-
tion coefficient and corresponding p-values were subse-
quently plotted per subset of peaks.
Classification performance of the data sets obtained with
both apparatus was assessed by building classification
trees with the Biomarker Patterns Software (BPS; Bio-Rad
Labs). Trees were generated with the gini method and the
minimal cost tree was chosen in both the CRC and BC
sample set. A ten-fold cross validation was used to esti-
mate the sensitivity and specificity for each tree.
For the CM10 and IMAC30 serum fractionation sets, base-
line correction and noise calculation was performed as
described for the CRC and BC set. For each duplicate frac-
tion, peaks were auto-detected by the ProteinChip soft-
ware or Ciphergen Express™ by the settings described in
Table 1. The number of peaks in each fraction was
assessed, as well as the number of unique peaks across all
fractions.
Results
Protein profiling CRC set
Six spectra did not contain a protein profile and were thus
not assessable (Table 1). For data set 1a normalisation fac-
tors as estimated by the apparatus-associated software of
the assessable spectra were 0.67 to 3.39 (log -0.18 to 0.53)
and for data set 1b 0.62 to 2.4 (log -0.21 to 0.38). For data
set 2 values ranged from 0.33 to 4.8 (log -0.49 to 0.68).
Since the spectra with aberrant normalisation factors (>2
SD from mean of log normalisation factor) were mostly
not from the same samples for the two apparatus, none
were excluded, to ensure an equal comparison of both
machines. This concerned 13 and 11 spectra from data set
1a and 1b, and 14 from data set 2.
Comparing CRC vs. CON, 32 clusters were generated for
data set 1a (Table 2). In contrast, despite similar settings
for processing and the same spectra, only 27 clusters were
generated for data set 1b. With the PCS 4000 (data set 2)
48 clusters could be detected. Although the number of
detected peaks was highest for data set 2, data set 1a
yielded a similar number of significantly different peaks.
Detailed peak cluster information can be found in Table
Table 1: Settings for protein profiling and data processing
CRC sample set BC sample set
PBS-IIc PCS 4000 PBS-IIc PCS 4000
SELDI analysis parameters
Samples CRC: n = 45
CON: n = 43
BC: n = 45
CON: n = 46
Array type CM10 IMAC30 Ni
Binding conditions 20 mM NaAc pH 5 PBS pH 7.4/0.5 M NaCl
Replicates 3 2
SELDI acquisition parameters
m/z range 0–200 kDa 0–200 kDa 0–200 kDa 0–200 kDa
Laser intensity 155 3500 nJ 155 3500 nJ
Detector sensitivity 6 n.a. 5 n.a
Deflector/detector 
attenuation
2000 Da 2000 Da 1000 Da 1000 Da
Laser shots kept 65 530 105 530
Not-assessable spectra CRC: 2/135
CON: 4/129
BC: 4/90
CON: 0/92
Cluster settings:
First pass S/N 5 Valley depth 5 S/N 5 Valley depth 5
Second pass S/N 2 Valley depth 2 S/N 2 Valley depth 2
Cluster mass window 0.3% 0.3% 0.3% 0.3%
Present in 45% 45% 30% 30%
n.a.: not applicableBMC Medical Genomics 2008, 1:4 http://www.biomedcentral.com/1755-8794/1/4
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3. Overall, the significantly different peaks in all data sets
were largely similar.
Classification trees were built with all clustered peaks in
each data set and with the subset of the 25 clusters that
were detected in all three data sets (Table 4). The best tree
was generated with data set 2, with m/z 4446 as single
classifier and sensitivity and specificity ≥ 80%. Since this
peak was not detected in data set 1a and 1b, other peaks
were used as classifiers in these sets, respectively m/z
15930 and 32308. The classification trees constructed on
the subset of 25 common clusters in data sets 1a and 1b
applied the same cluster (m/z 32308). The best classifier
of data set 2 made use of apparently the same cluster (m/
z 32394), and had a better performance as single classifier
in this set than in set 1a, but a similar performance as in
set 1b.
Protein profiling BC set
Following array reading with both the PCS 4000 and PBS-
IIc apparatus, two spectra did not contain a protein pro-
file. Along with their duplicate reading, these spectra were
excluded from further analyses (Table 1). The normalisa-
tion factors for data set 1a were 0.52 to 2.15 (log -0.29 to
0.33). Using Ciphergen Express™ software, normalisation
factors of all spectra ranged from 0.51 to 2.25 (log -0.29
to 0.35) for the PBS-IIc generated spectra and from 0.44 to
2.69 (log -0.36 to 0.43) for the PCS 4000 generated spec-
tra. In total, 9 and 8 spectra from data set 1a and 1b
respectively and 10 spectra from data set 2 had an aberrant
normalisation factor (>2 SD from mean of log normalisa-
tion factor). As the majority of these spectra were from dif-
ferent samples for the 3 datasets, none were excluded, to
ensure equal comparison of both apparatus. In data set 1a
and 1b respectively, a total of 81 and 31 clusters were
detected. The ProteinChip software detected 51 clusters
that were not detected by Ciphergen Express™ in the same
dataset. Except for one cluster (>100 kDa), these unique
clusters were all < 10 kDa in mass and < 4 in intensity. In
the data set 2, a total of 59 peak clusters was detected. Fif-
teen of these clusters (all > 9 kDa) were not detected in
either data set 1a or 1b. Tables 2 and 3, respectively, pro-
vide an overview of peak clustering results and detailed
peak cluster information.
Classification trees were generated on all peaks detected in
data set 1a, 1b or 2, and on the subset of peaks detected
across all three data sets (Table 5). All optimum decision
trees constructed on data set 1a and 1b, using either all
peaks detected or only the common peaks, applied m/z
3964 as single classifier, with data set 1b yielding the best
performance of ~80%. The trees constructed on data set 2
made use of different clusters, either considering all peaks
detected (m/z 9151 and m/z 5360) or the common peaks
detected (m/z 3979 and m/z 4218). However, the tree
constructed on data set 1b generally had the best perform-
ance.
Reproducibility CRC set
For each data set on each apparatus the inter-chip repro-
ducibility was assessed by calculating the median CV
across all samples from replicate peak intensities of all
clustered peaks and of the subset of 25 common peaks in
the three data sets. The median CV of all peaks and all
common peaks was lowest for data set 2 and highest for
data set 1a (Table 6). Considering all peaks, the CV was
significantly different for the data sets (Kruskall Wallis
test; p = 0.012), but not when considering only the com-
mon peaks to each data set (Kruskall Wallis test; p = 0.3).
Reproducibility BC set
For the BC sample set, Spearman's rank correlation coeffi-
cient was calculated on peak intensities in each duplicate
analysis for successive subsets of peaks including the 10%,
20%, 30% to 100% of peaks with lowest intensity, for all
three data sets. As depicted in Figure 1, a correlation coef-
ficient > 0.8 was only reached after inclusion of 80% of
lowest peaks in data set 1a, while in the other two data
sets, this coefficient was already reached at inclusion of <
20% of lowest peaks. Similar results were obtained when
considering the significance of correlation (Figure 1).
However, when considering only the common peaks
Table 2: Peak clustering results for the CRC and BC sample sets
Number of peaks detected in: CRC sample set BC sample set
all p* < 0.01 all p* < 0.01
Data set 1a 32 19 81 47
Also detected in data set 1b 31 13 30 22
Also detected in data set 2 31 15 43 28
Data set 1b 27 14 31 22
Also detected in data set 2 26 11 29 21
Data set 2 48 20 59 45
* MWU testBMC Medical Genomics 2008, 1:4 http://www.biomedcentral.com/1755-8794/1/4
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Table 3: Peak cluster information for the CRC and BC sample set
CRC sample set clusters (Da) BC sample set clusters (Da)
Data set 1a Data set 1b Data set 2 Data set 1a Data set 1b Data set 2
2746* 2745* 2746* 2027 2028
3163 2146* 2146*
3406* 2154*
3979* 3978* 2235*
4160 4162 4159 2277*
4179* 4181* 4182* 2647
4290* 4287* 2675*
4303 2731*
4446* 2747
4481 4474 4480 2760 2760*
4605 4607 2775
4961 2794
5723* 5724* 5719* 2888*
5913* 5915* 2960* 2961*
6443 6443 6442 2968*
6459* 6460* 6458* 3091
6641 6640 6643 3107
6655* 6654* 6659* 3151*
6687 3168* 3165* 3164*
6846 3282* 3281* 3281*
6860* 6865* 3296*
7778 7779 7778 3431
7982* 7982* 7990* 3451
8079* 8074* 3689* 3683*
8159 3781*
8889 3824
8968* 8962* 8962* 3891* 3891*
9186 9187 3898
9210 3916*
9307* 9307* 9315 3965* 3963* 3962*
9360 3980* 3980* 3979*
9409 3995* 3997* 3994*
9593 4078
10072* 4137 4138
12889 4155
13779* 13778* 13796 4204*
14077* 14077* 14053 4218* 4218* 4218*
15121 15121 15168 4292* 4292* 4289*
15930* 15919* 15982* 4308* 4308* 4304*
16105* 16105* 16139* 4334*
16334* 4449* 4447* 4444*
18617* 4464* 4463* 4458*
23426* 23426 23486 4484* 4484* 4482*
28098* 28093 28216 4497*
32308* 32308* 32394* 4513*
39727 4653 4652 4650
51034 51006 51116 4669
56408 56337 56685 4691
67003 67003 67239 4798
79100 79040 80075 5076 5078
5090
5274*
5348* 5348* 5348*
5363* 5364* 5360*
5554* 5549*
5815 5810
5916* 5917* 5915*BMC Medical Genomics 2008, 1:4 http://www.biomedcentral.com/1755-8794/1/4
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detected across all three data sets, results obtained were
highly similar for the three data sets (Figure 2).
Serum fractionation
The numbers of clusters detected on CM10 and IMAC
arrays for each sample in each acquired fraction are sum-
marised in Table 7. Some of the clusters are occurring in
5932* 5932* 5929*
6100* 6097*
6122* 6122* 6121*
6142* 6136*
6667 6676
6848
6965* 6972* 6966*
6990*
7482
7778 7778 7775
7939*
7985 7982
8155 8155 8150
8948* 8955* 8946*
9161* 9151*
9302 9303 9299
9526
11096*
11747*
13925* 13925* 13919*
14124*
22284*
28221
30502*
33475* 33583* 33490*
40059*
43108 43015 43098*
50704*
60776 60804 60889*
66702* 66711* 67142*
79724 79393 80323*
89750*
91037
93689*
104178*
109494 110344*
133447 133435
136611*
149723 149579*
177011
* MWU test; p < 0.01
Table 3: Peak cluster information for the CRC and BC sample set (Continued)
Table 4: Characteristics of the classification trees constructed on the CRC sample set
Tree characteristics: Tree performance*:
Data set Clusters (#) Node 1 Node 2 Sens (%) Spec (%)
1a All (32) m/z 15930 ≤ 35.576 m/z 51034 ≤ 1.372 68.8 62.8
Common (25) m/z 15930 ≤ 35.576 m/z 51034 ≤ 1.372 68.8 62.8
1b All (27) m/z 32308 ≤ 0.676 - - 75.6 73.8
Common (25) m/z 32308 ≤ 0.676 - - 75.6 73.8
2A l l ( 4 8 ) m / z  4 4 4 6 ≤ 1.136 - - 82.2 90.5
Common (25) m/z 32394 ≤ 0.149 - - 73.3 81.0
* tree performance as determined by 10-fold cross validation, sens: sensitivity, spec: specificityBMC Medical Genomics 2008, 1:4 http://www.biomedcentral.com/1755-8794/1/4
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several fractions. Ignoring these overlapping clusters, on
average twice as many peaks were detected in the PCS
4000 generated spectra compared to the PBS-IIc generated
spectra (analysed either by the ProteinChip software or
Ciphergen Express™). This is also illustrated in Figure 3.
Discussion
Although the PBS-IIc SELDI-TOF MS apparatus has been
extensively used in the search for better biomarkers, issues
have been raised concerning the semi-quantitative nature
of the technique and its reproducibility. To overcome
these limitations, a new SELDI-TOF MS instrument has
been introduced: the PCS 4000 series. In the current
study, we compared the performances of the old PBS-IIc
and new PCS 4000 series generation SELDI-TOF MS appa-
ratus, by analysis of two sample sets.
Peak detection
For the CRC sample set, most peaks were detected with
the new PCS 4000 series using the Ciphergen Express™
software, indicating a better sensitivity and less detector
saturation of this apparatus. The latter allows for the
application of increased laser intensities, after which pro-
teins will desorb more comprehensively, resulting in
detection of more peaks. However, for the BC sample set,
most peaks were detected with the PBS-IIc instrument
using the ProteinChip software, indicating the opposite.
Interestingly, in both sample sets, fewer peaks were
detected by Ciphergen Express™ than by the ProteinChip
software in the spectra generated with the PBS-IIc, despite
the fact that both software packages use the same algo-
rithm with similar settings to generate peak clusters.
Apparently, the spectrum processing algorithms underly-
ing the visible settings are different for both software pack-
ages.
In the BC set, all peaks detected in the PBS-IIc generated
spectra by the ProteinChip software, but missed by
Ciphergen Express™ were < 4 in intensity. As peaks are
detected by means of their signal-to-noise ratio, detection
of these low intensity peaks becomes critical when either
the noise increases or the signal decreases due to over-esti-
mation of the baseline. Conceivably, the algorithm for
noise and/or baseline estimation between both software
packages has been changed. Due to the detector attenua-
tion of the PCS 4000 instrument, matrix blanking has
improved compared to the PBS-IIc. Hence, less chemical
noise is expected when measuring with the PCS 4000
instrument, to which the algorithm applied in noise cal-
culation might have been adapted. As such, for spectra
generated with the PBS-IIc (in which relatively more
chemical noise is present), the Ciphergen Express™ soft-
ware will estimate the noise too high or the signal too low,
the latter being the consequence of the baseline being esti-
mated too high. Either way results in fewer detected peaks.
The difference between peaks detected by either software
package in the PBS-IIc generated spectra was more pro-
nounced in the BC set than in the CRC set. These two data-
sets differed in their deflector/detector attenuation
settings (CRC: 2000 Da, BC: 1000 Da), but in both sets,
the noise was calculated between 2 and 200 kDa. How-
Table 5: Characteristics of the classification trees constructed on the BC sample set
Tree characteristics: Tree performance*:
Data set Clusters (#) Node 1 Node 2 Sens (%) Spec (%)
1a All (81) m/z 3964 ≤ 4.010 - - 74.4 73.9
Common (28) m/z 3964 ≤ 4.010 - - 74.4 73.9
1b All (31) m/z 3964 ≤ 3.855 - - 83.7 78.3
Common (28) m/z 3964 ≤ 3.855 - - 83.7 78.3
2A l l ( 5 9 ) m / z  9 1 5 1 ≤ 1.614 m/z 5360 ≤ 17.856 72.1 78.3
Common (28) m/z 3979 ≤ 32.163 m/z 4218 ≤ 4.648 62.8 71.7
* tree performance as determined by 10-fold cross validation, sens: sensitivity, spec: specificity
Table 6: Reproducibility of the CRC data sets
Peak clusters: Median CV of:
Data set 1a Data set 1b Data set 2
All peaks 28.30% 22.61% 20.62%
Common peaks 25.48% 23.06% 21.71%
All peaks (CON) 28.52% 21.76% 18.50%
All peaks (CRC) 27.68% 23.38% 23.33%BMC Medical Genomics 2008, 1:4 http://www.biomedcentral.com/1755-8794/1/4
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ever, as matrix peaks are generally observed up to 2000
Da, their contribution to the noise will most likely
increase with decreasing deflector settings. Hence, the dif-
ference in deflector settings could have caused higher
noise estimation in the BC set compared to the CRC set.
Combined with the probable noise overestimation by
Ciphergen Express™ in PBS-IIc generated spectra, and the
fact that relative to the CRC data sets, the BC data sets con-
tained more low intensity peaks (30 and 70%, respec-
tively), which were mainly present in the <10 kDa range,
this might explain the more pronounced difference in
number of peaks detected in the PBS-IIc generated BC
dataset by both software packages.
The difference in deflector/detector attenuation settings
might also explain why, contrary to the CRC set, in the BC
set more peaks were detected by the ProteinChip software
in the PBS-IIc spectra than by Ciphergen Express™ in the
PCS 4000 spectra. Compared to the ProteinChip software,
the noise calculation algorithm in Ciphergen Express™
apparently is more sensitive to the noise in the low molec-
ular weight range. Due to the difference in detector atten-
uation settings, this low molecular weight range will
contain a higher signal in the BC spectra than in the CRC
spectra. Consequently, the noise is estimated higher and
less peaks are detected. This hypothesis is supported by
the observation that all peaks detected in the PBS-IIc spec-
tra, but not in the PCS 4000 spectra were < 3 in intensity.
One of the alleged improvements of the PCS 4000 com-
pared to its PBS-IIc predecessor is its special configuration
for sensitivity in the high mass range that allows detection
Plots of Spearman's rank correlation coefficient and p-values  for common peaks detected in the BC data sets Figure 2
Plots of Spearman's rank correlation coefficient and 
p-values for common peaks detected in the BC data 
sets. Depicted are the mean (red) and median (black) values 
of common peaks detected across all three data sets of the 
BC sample set. PBS: data set 1a (PBS-IIc generated data, ana-
lysed by ProteinChip software), PCS: data set 2 (PCS 4000 
generated data, analysed by Ciphergen Express™), PBS/PCS: 
data set 1b (PBS-IIc generated data, analysed by Ciphergen 
Express™).
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Plots of Spearman's rank correlation coefficient and p-values  for all peaks detected in the BC data sets Figure 1
Plots of Spearman's rank correlation coefficient and 
p-values for all peaks detected in the BC data sets. 
Depicted are the mean (red) and median (black) values of all 
peaks detected in the three data sets of the BC sample set. 
PBS: data set 1a (PBS-IIc generated data, analysed by Protein-
Chip software), PCS: data set 2 (PCS 4000 generated data, 
analysed by Ciphergen Express™), PBS/PCS: data set 1b 
(PBS-IIc generated data, analysed by Ciphergen Express™).
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of proteins above 100 kDa. Indeed, in the BC set, four >
100 kDa peaks were detected exclusively in the PCS 4000
generated spectra, compared to two peaks in the PBS-IIc
generated spectra. Moreover, all peaks that were detected
exclusively in the PCS 4000 spectra by Ciphergen
Express™ were above 10 kDa. However, in none of the
CRC data sets any proteins > 100 kDa were detected, indi-
cating no better sensitivity for proteins in the higher mass
range for the PCS 4000 series. Most peaks detected only in
data set 2 were in the 2–10 kDa range. The differences in
detection of high molecular weight peaks could, however,
be caused by the different array types used for the analyses
of both sample sets.
Classification
As the ultimate gain of the improved performance of the
PCS 4000 instrument would be detection of more and
better biomarker candidates, we also assessed the classifi-
cation potential of the data sets generated by both
machines. For the CRC set, the improved performance of
the new instrument was indeed reflected in the classifiers
constructed, as the best classification was obtained with
the data set generated by the PCS 4000 instrument, using
the total number of peaks detected. When using the subset
of peaks detected in all three datasets, the performance of
the classifier build on dataset 1b and 2 was similar. For the
BC data set, results were less unambiguous. While for data
set 1a and 1b only one classifier was applied in the differ-
ent optimum decision trees constructed, best performance
was achieved in data set 1b. Apparently, the different spec-
trum processing algorithms underlying both software
packages also contribute to the alleged improved perform-
ance of the PCS 4000 instrument. However, application of
both the PCS 4000 and Ciphergen Express™ yielded no
better classifiers. Hence, for the BC set, the superior per-
formance of the PCS 4000 instrument in providing better
biomarker candidates could not be confirmed. It can,
Table 7: Peak clustering results for the serum fractions profiled on CM10 and IMAC30 arrays
Data set: Serum sample 1 Serum sample 2 Serum sample 3
CM10 IMAC30 CM10 IMAC30 CM10 IMAC30
1a 1b 2 1a 1b 2 1a 1b 2 1a 1b 2 1a 1b 2 1a 1b 2
FT+pH9 43 24 60 23 22 52 59 23 57 28 22 43 29 19 47 24 15 47
p H 7 1 66 4 59 9 3 02 894 69 72 49 55 17 72 6
p H 5 4 21 95 11 51 53 23 71 6 4 92 41 6 2 92 11 5 5 61 71 1 2 8
p H 4 2 22 24 62 42 25 31 91 7 5 03 42 4 5 42 31 9 5 42 32 1 4 6
pH3 20 20 46 16 14 42 10 8 48 16 13 36 19 16 58 18 13 38
O r g a n i c 2 21 75 83 13 04 01 71 2 6 12 21 5 3 62 42 0 5 31 92 0 4 2
Total 165 108 306 118 112 249 170 85 311 133 97 222 125 94 319 108 87 227
Unique 103 78 167 85 82 158 106 61 162 82 72 135 82 71 163 67 53 128
Spectra of serum fractions analysed on CM10 arrays and measured on the PBS-IIc and PCS 4000 instrument Figure 3
Spectra of serum fractions analysed on CM10 arrays and measured on the PBS-IIc and PCS 4000 instrument. 
A: flow through/pH 9 fractions, B: pH 7 fractions.BMC Medical Genomics 2008, 1:4 http://www.biomedcentral.com/1755-8794/1/4
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however, not be precluded that our data sets do not con-
tain any real biomarkers.
Reproducibility
For the CRC set, the reproducibility of peak intensities was
largely similar across data sets, although a non-significant
trend could be seen to a lower CV for data set 2 compared
to 1a and 1b. Thus, the spot scanning in a raster and the
less detector saturation with the PCS 4000 series does not
seem to result in a significant better reproducibility. The
fact that significant differences in CV were seen when all
peaks were considered indicates that the surplus of peaks
detected in data set 2 consists of more robust peaks than
the ones also detected in the other data sets, causing the
median CV to drop. Reproducibility of the PCS 4000
instrument as measured by the CV has been stated to be <
20% using an external standard [13]. It is not known to us
in which m/z range this reproducibility was obtained and
whether this was with manual or robotic sample han-
dling. However, our observed median CV is well in con-
cordance with this value, especially taking the manual
sample handling into account.
Reproducibility in the BC data sets was assessed by calcu-
lation of Spearman's rank correlation coefficient on dupli-
cate intensities of the 10 to 100% peaks with lowest
intensity. When all peaks detected were included in this
calculation, usage of the PCS 4000 and Ciphergen
Express™ software package led to a better performance, as
statistically significantly (p < 0.05) good correlations (R >
0.8) were already achieved upon inclusion of only 20% of
lowest peaks, compared to the 80% of lowest peaks neces-
sary to achieve comparable results in the PBS-IIc gener-
ated data set. However, when correcting for the excess of
low intensity peaks detected in data set 1a relative to data
set 2 by considering only the peaks detected across all
three data sets, results obtained were highly similar for the
three data sets. Thus, the improved features of the PCS
4000 instrument relative to the PBS-IIc apparatus do not
lead to an improved reproducibility, as already observed
in the CRC data sets.
Serum fractionation
Analysis of the PBS-IIc generated spectra by Ciphergen
Express™ generally yielded the lowest number of peaks
detected. Hence, the performance of the PCS 4000 in
serum fractionation is indeed superior compared to the
PBS-IIc instrument, reflecting the improved spot coverage
and increased detector sensitivity. These observations are
highly similar to the results obtained following peak
detection in the three CRC data sets.
Although deflector/detector attenuation settings were dif-
ferent for the fractionation spectra on IMAC and CM10
chips, peak clustering results were highly similar for the
two array types used, contrary to the results obtained in
the CRC and BC sample sets. This could be due to the fact
that these spectra have a higher noise level than spectra
from crude serum (data not shown), limiting the influ-
ence of the different noise estimation between both soft-
ware packages. Moreover, the number of peaks < 10 kDa
is similar in the fractionation spectra from the IMAC and
CM10 chips, contrary to the spectra from the CRC and BC
set, which could also cause less influence of the noise esti-
mation on peak detection.
Conclusion
In conclusion, regarding the number of peaks detected,
the biomarker potential and the reproducibility of the two
sample sets investigated by both the old (PBS-IIc) and
new (PCS 4000) generation SELDI-TOF MS apparatus, we
could not confirm the alleged improved performance of
the PCS 4000 instrument over the PBS-IIc apparatus.
However, the PCS 4000 instrument did prove to be of
superior performance in peak detection following profil-
ing of serum fractions. Until now, the majority of studies
in which SELDI-TOF MS was applied in crude serum pro-
tein profiling for biomarker discovery generally reported
high abundant, non-disease-specific proteins as potential
biomarkers. However, the large dynamic range of crude
serum hampers detection of the allegedly high-informa-
tive low abundant serum proteins. As serum fractionation
facilitates detection of low abundant proteins through
reduction of this dynamic range, it is increasingly applied
in the search for new potential biomarkers. Hence,
although the new PCS 4000 instrument did not differ
from the old PBS-IIc apparatus in the analysis of crude
serum, its superior performance of fractionated serum
samples does hold promise for improved biomarker
detection and identification.
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